Publications by authors named "B O Lindmark"

Claim this Profile
T
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations.
Jesper Kammersgaard Christensen, Nicholas Colletti, Shirin Hooshfar, Rongrong Rosa Jiang, Carol Kuo, Bosse Lindmark

Nucleic Acids Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting report: DMDG peptide and oligonucleotide ADME workshop 2024.
Inga Bjørnsdottir, Ralf Lotz, Bo Lindmark, Steve Hood, Jesper Kammersgaard Christensen

Xenobiotica· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
Amina Z Haggag, Jianfeng Xu, Laurie Butcher, Sandra Pagnussat, Graeme Davies, Bosse Lindmark

Diabetes Obes Metab· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment.
Vassilios Aslanis, Michael Gray, Robert J Slack, Fredrik R Zetterberg, Dimitar Tonev, Bertil Lindmark

Clin Drug Investig· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.
Xue-Qing Li, Bo Lindmark, Carl Amilon, Kristin Samuelsson, Lars Weidolf

Pharmacol Res Perspect· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis